EADV News 55

News S UMM E R 2 01 5 – N ° 5 5

Psoriasis: towards targeted personalised treatment

Current model of the maintenance phase of psoriasis

New potential targets (including members of the IL-1 family of cytokines and receptors) have been recognised by the identification of genes responsible for some monogenic variants of psoriasis (Figure 2), and the management of pustular psoriasis can be expected to become greatly improved. vi Increasing knowledge of the mechanisms

Prof Luis Puig

P soriasis might be the best example in dermatology of the dramatic therapeutic advances which have arisen from the successful collaboration between scientists and clinicians i . Our therapeutic weapons have evolved from serendipitous findings to design drugs and genetically engineered biologicals targeted to the key cytokines involved in the pathogenesis of the disease. Technological advances have resulted in greater insight into the genetic basis of the disease, providingmechanistic explanations for the efficacy of some treatments and potential targets for the development of new ones. The IL-23/IL-17 axis ii has been identified as the keystone bridging innate and adaptive immunity alterations with keratinocyte activation, proliferation and abnormal differentiation, and its blockade by biological agents (Figure 1) has been proven to result in fast responses of unparalleled depth that are likely to define complete or nearly complete blanching as a new therapeutic paradigm for psoriasis. iii We can expect psoriasis treatment to become increasingly individualised, customising drug exposure according to serum trough concentrations and using

determinations of antidrug antibody levels to complement clinical acumen for decisions regarding drug switching in patients with primary failure or secondary loss of response. Patient genotyping may contribute to refining our therapeutic choice; for instance, HLACw6 haplotype is emerging as a predictor of improved response following treatment with ustekinumab iv and probably other biologics targeting the adaptive immune response. Minimising immunogenicity Design improvements and patient selection will undoubtedly minimise the immunogenicity of currently available biologics, but better guidance is required as regards prevention or reversal of anti- drug antibody production by combination treatment, v and we need refined algorithms for treating selected patients intermittently or on demand.

continued on page 10 ss

In this issue

Editorial.......................................................................... 3 Finance Committee Update...................................... 3 President's Perspective............................................... 4 Notice of AGM............................................................. 5 Patients' Information: EULAR.................................. 6 EADV in China and India........................................... 7 EADV Specialist Courses: steep growth................ 8 Fostering Course: Genodermatoses...................... 11 24 th EADV Congress – Copenhagen.....................12 Dermatology in Russia.............................................14 Call for Nominations: - Board Directors.......................................................15 - Committee Members.............................................16 - Task Forces Facilitator..........................................17 - Editor of EADV News .............................................18 Scholarship applications - Athens 2016............19 CME-CPD Statistics from Valencia......................20 Scholarship winners – Valencia............................21 Scenes from the EADV Spring Symposium – Valencia........................................................................22 Calendar of Events ...................................................23

International Collaboration EADV in China and India

24 th EADV Congress 2015 – Copenhagen New: Aesthetic Sunday

Call for Scholarship Applications 13 th EADV Spring Symposium 2016 - Athens, Greece See page 19 ss

See page 7 ss

See page 12 ss

EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

ACADEMIE EUROPÉENNE DE DERMATOLOGIE ET VÉNÉRÉOLOGIE

Made with